Aussie Pharma Pharmaxis Submits Bronchitol Application to China’s State FDA
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based Pharmaxis submitted a clinical trial application to China's State FDA for chronic lung condition drug Bronchitol (mannitol) for treatment of bronchiectasis, the company announced March 7